High-dose contrast-enhanced MRI in multiple sclerosis

Area of Science:

• Radiology
• Neurology
• Medical Imaging

Background:

• Contrast-enhanced magnetic resonance imaging (MRI) is crucial for evaluating disease activity in multiple sclerosis (MS).
• It serves as a potential outcome measure for assessing therapeutic efficacy in clinical trials.
• Comparing different contrast agents is essential for optimizing diagnostic sensitivity.

Purpose of the Study:

• To compare the sensitivity of a high dose of gadolinium-HP-DO3A against a standard dose of gadolinium-DTPA.
• To evaluate the impact of contrast agent dose on detecting active lesions in relapsing-remitting MS.

Main Methods:

• 16 patients with relapsing-remitting MS in the acute phase underwent two MRI scans within 48 hours.
• The first MRI used a standard dose of gadolinium-DTPA (0.1 mmol/kg).
• The second MRI used an experimental high dose of gadolinium-HP-DO3A (0.3 mmol/kg).

Main Results:

• The high-dose gadolinium-HP-DO3A study identified significantly more enhancing lesions (56) compared to the standard-dose gadolinium-DTPA (38).
• This difference was particularly notable for infratentorial and smaller lesions.
• A marked improvement in lesion visibility and delineation was observed with the higher dose contrast agent.

Conclusions:

• High-dose gadolinium-HP-DO3A demonstrates superior sensitivity in detecting active lesions in MS compared to standard gadolinium-DTPA.
• This enhanced sensitivity can improve the assessment of MS disease activity.
• Gadolinium-HP-DO3A may offer a more effective tool for MS clinical trials.